Evidence mapPaperPMID 41754870Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Cannabidiol in Neurology: Current Insights and Translational Perspectives.

Magdalena Białoń, Marta Kędziora, Katarzyna Starowicz

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Magdalena BiałońDepartment of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland.ORCID 0000-0003-1440-1932
Marta KędzioraDepartment of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland.ORCID 0000-0002-6980-8273
Katarzyna StarowiczDepartment of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland.ORCID 0000-0003-0091-0066

Funding

The National Science Centre, Poland 2021/43/B/NZ7/01162TrePsy project from the European Union's Horizon Europe 101079256
6 · The paper itself

Abstract

Cannabidiol (CBD) is one of the most studied compounds of

Indexed as

Alzheimer’s diseasecannabidiol (CBD)Epidiolexepilepsymultiple sclerosisnabiximolsneuropathic painParkinson’s diseasestroketraumatic brain injury

Identifiers

PMID41754870
PMCPMC12943572

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.